Federated Hermes Inc. Has $24.89 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Federated Hermes Inc. reduced its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,056,241 shares of the company's stock after selling 160,929 shares during the quarter. Federated Hermes Inc. owned about 1.04% of Dyne Therapeutics worth $24,885,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Springhill Fund Asset Management HK Co Ltd acquired a new position in Dyne Therapeutics during the fourth quarter worth about $3,091,000. Wells Fargo & Company MN raised its holdings in shares of Dyne Therapeutics by 54.5% in the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock worth $913,000 after purchasing an additional 13,677 shares in the last quarter. Trexquant Investment LP lifted its stake in Dyne Therapeutics by 95.6% during the fourth quarter. Trexquant Investment LP now owns 125,378 shares of the company's stock valued at $2,954,000 after purchasing an additional 61,288 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Dyne Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock worth $44,476,000 after buying an additional 27,916 shares in the last quarter. Finally, Schroder Investment Management Group grew its position in Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after buying an additional 56,961 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company's stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 6,237 shares of company stock valued at $77,760 in the last quarter. Insiders own 20.77% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on DYN shares. JPMorgan Chase & Co. cut their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Chardan Capital reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, March 17th. Piper Sandler decreased their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN traded up $0.20 during mid-day trading on Monday, reaching $7.24. 200,261 shares of the company traded hands, compared to its average volume of 1,468,248. The company's fifty day moving average is $11.86 and its two-hundred day moving average is $21.24. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The stock has a market cap of $819.00 million, a PE ratio of -2.03 and a beta of 1.21.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. Research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.